Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

By Kara Nyberg, PhD Posted: August 2018 The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint...

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Posted: December 2018 In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical...

Immunotherapy Adverse-Event Treatment Resource Guide

The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline...

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to...

By Ross Soo, MB BS, PhD, FRACP Posted: December 2018 The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs)...

Management of Immunotherapy Toxicity in NSCLC

By Beth Eaby-Sandy, MSN, CRNP Posted: February 2018 When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was...

Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC

By Mariano Provencio-Pulla, MD, PhD Posted: December 2018 Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of...

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For...

IMpower133: Finally Moving the Needle in SCLC

By Stephen V. Liu, MD Posted: March 1, 2019 The addition of atezolizumab to standard chemotherapy for extensive-stage SCLC achieved what, for decades, had been beyond...

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting...

Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC

Posted: March 1, 2019 In the following interview, Jamie E. Chaft, MD, a medical oncologist at the Memorial Sloan Kettering Cancer Center, discusses new data...

Meeting News